ABSTRACT
A book focusing on transnational perspectives on BRCA would certainly be incomplete without a chapter on the international uproar regarding patents on the BRCA gene sequences and testing methods. BRCA ‘gene patents’ have been the focus of intense controversy for decades and – more recently – the subject of court battles in the US and Australia. Most conspicuously, the US Supreme Court handed down its ruling on whether human genes are patentable subject matter on 13 June, 2013 (AMP v. Myriad [2013]).
